{
  "date": "2025-12-03T21:09:07.192627",
  "benchmark_type": "efficacy_predict",
  "test_file": "test_cases_pilot.json",
  "num_cases": 10,
  "aggregate_metrics": {
    "drug_accuracy": 0.5,
    "evo2_usage_rate": 1.0,
    "avg_confidence": 0.5125000000000001
  },
  "results": [
    {
      "case_id": "SL_001",
      "ground_truth": {
        "synthetic_lethality_detected": true,
        "known_sl_pairs": [
          "BRCA1+PARP"
        ],
        "effective_drugs": [
          "Olaparib",
          "Niraparib",
          "Rucaparib"
        ],
        "broken_pathways": [
          "HR"
        ],
        "essential_pathways": [
          "PARP"
        ],
        "depmap_essentiality": {
          "BRCA1": 0.92
        },
        "clinical_evidence": {
          "olaparib_fda_approved": true,
          "olaparib_indication": "BRCA-mutated ovarian cancer",
          "response_rate": 0.65
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.545
      },
      "metrics": {
        "drug_match": true,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.545,
        "efficacy_score": 0.465,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.465,
            "confidence": 0.545,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.522,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.465,
            "confidence": 0.545,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.522,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.465,
            "confidence": 0.545,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.522,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.465,
            "confidence": 0.545,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.522,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.0,
            "confidence": 0.258,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.522,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.0,
            "confidence": 0.258,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.C61G ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.522,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          }
        ],
        "run_signature": "96c5a847-37d3-4ccc-987c-f7dbe1141232",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "consider",
        "provenance": {
          "run_id": "96c5a847-37d3-4ccc-987c-f7dbe1141232",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 1
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.545,
            "tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "S_contribution": 0.05,
            "P_contribution": 1.0,
            "E_contribution": 0.0,
            "pathway_disruption": {
              "ddr": 0.05
            }
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_002",
      "ground_truth": {
        "synthetic_lethality_detected": true,
        "known_sl_pairs": [
          "BRCA2+PARP"
        ],
        "effective_drugs": [
          "Olaparib",
          "Niraparib"
        ],
        "broken_pathways": [
          "HR"
        ],
        "essential_pathways": [
          "PARP"
        ],
        "depmap_essentiality": {
          "BRCA2": 0.88
        },
        "clinical_evidence": {
          "olaparib_fda_approved": true,
          "response_rate": 0.6
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.57
      },
      "metrics": {
        "drug_match": true,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.57,
        "efficacy_score": 0.76,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.76,
            "confidence": 0.57,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.2,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.406,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.76,
            "confidence": 0.57,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.2,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.406,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.76,
            "confidence": 0.57,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.2,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.406,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.76,
            "confidence": 0.57,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.2,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.406,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.3,
            "confidence": 0.52,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.406,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.3,
            "confidence": 0.52,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.K3326* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.406,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          }
        ],
        "run_signature": "d78eed99-e083-400a-9b73-088daabf2e26",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "consider",
        "provenance": {
          "run_id": "d78eed99-e083-400a-9b73-088daabf2e26",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 1
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.57,
            "tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "S_contribution": 1.0,
            "P_contribution": 1.0,
            "E_contribution": 0.2,
            "pathway_disruption": {
              "ddr": 1.0
            }
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_003",
      "ground_truth": {
        "synthetic_lethality_detected": true,
        "known_sl_pairs": [
          "MBD4+PARP",
          "TP53+ATR"
        ],
        "effective_drugs": [
          "Olaparib",
          "Ceralasertib"
        ],
        "broken_pathways": [
          "BER",
          "G1/S Checkpoint"
        ],
        "essential_pathways": [
          "HR",
          "ATR/CHK1"
        ],
        "depmap_essentiality": {
          "MBD4": 0.8,
          "TP53": 0.75
        },
        "clinical_evidence": {
          "olaparib_fda_approved": true,
          "ceralasertib_status": "clinical_trials"
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.66
      },
      "metrics": {
        "drug_match": true,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.66,
        "efficacy_score": 0.75,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.75,
            "confidence": 0.66,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.685,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.75,
            "confidence": 0.66,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.685,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.75,
            "confidence": 0.66,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.685,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.75,
            "confidence": 0.66,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.685,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.35,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.685,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.35,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "MBD4 p.R346fs ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.685,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          }
        ],
        "run_signature": "99073858-9449-418f-8e01-c69d43a51eab",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "consider",
        "provenance": {
          "run_id": "99073858-9449-418f-8e01-c69d43a51eab",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 2
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.66,
            "tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "S_contribution": 1.0,
            "P_contribution": 1.0,
            "E_contribution": 0.0,
            "pathway_disruption": {
              "ddr": 1.0,
              "tp53": 0.8
            }
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_004",
      "ground_truth": {
        "synthetic_lethality_detected": true,
        "known_sl_pairs": [
          "TP53+ATR"
        ],
        "effective_drugs": [
          "Ceralasertib",
          "Adavosertib"
        ],
        "broken_pathways": [
          "G1/S Checkpoint"
        ],
        "essential_pathways": [
          "ATR/CHK1"
        ],
        "depmap_essentiality": {
          "TP53": 0.7
        },
        "clinical_evidence": {
          "ceralasertib_status": "clinical_trials"
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.58
      },
      "metrics": {
        "drug_match": false,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.58,
        "efficacy_score": 0.84,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.84,
            "confidence": 0.58,
            "evidence_tier": "consider",
            "badges": [
              "ClinVar-Strong",
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": "expert_panel",
              "prior": 0.2
            },
            "evidence_manifest": {
              "pubmed_query": "TP53 p.R273H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": "expert_panel"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.84,
            "confidence": 0.58,
            "evidence_tier": "consider",
            "badges": [
              "ClinVar-Strong",
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": "expert_panel",
              "prior": 0.2
            },
            "evidence_manifest": {
              "pubmed_query": "TP53 p.R273H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": "expert_panel"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.84,
            "confidence": 0.58,
            "evidence_tier": "consider",
            "badges": [
              "ClinVar-Strong",
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": "expert_panel",
              "prior": 0.2
            },
            "evidence_manifest": {
              "pubmed_query": "TP53 p.R273H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": "expert_panel"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.84,
            "confidence": 0.58,
            "evidence_tier": "consider",
            "badges": [
              "ClinVar-Strong",
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": "expert_panel",
              "prior": 0.2
            },
            "evidence_manifest": {
              "pubmed_query": "TP53 p.R273H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": "expert_panel"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.0,
            "confidence": 0.53,
            "evidence_tier": "insufficient",
            "badges": [
              "ClinVar-Strong"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": "expert_panel",
              "prior": 0.2
            },
            "evidence_manifest": {
              "pubmed_query": "TP53 p.R273H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": "expert_panel"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.0,
            "confidence": 0.53,
            "evidence_tier": "insufficient",
            "badges": [
              "ClinVar-Strong"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": "expert_panel",
              "prior": 0.2
            },
            "evidence_manifest": {
              "pubmed_query": "TP53 p.R273H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": "expert_panel"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          }
        ],
        "run_signature": "0812ac09-5aae-47dc-8d00-e487929c9d5f",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "consider",
        "provenance": {
          "run_id": "0812ac09-5aae-47dc-8d00-e487929c9d5f",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 1
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.58,
            "tier": "consider",
            "badges": [
              "ClinVar-Strong",
              "PathwayAligned"
            ],
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "S_contribution": 0.8,
            "P_contribution": 1.0,
            "E_contribution": 0.0,
            "pathway_disruption": {
              "tp53": 0.8
            }
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_005",
      "ground_truth": {
        "synthetic_lethality_detected": true,
        "known_sl_pairs": [
          "BRCA1+PARP",
          "TP53+ATR"
        ],
        "effective_drugs": [
          "Olaparib",
          "Ceralasertib"
        ],
        "broken_pathways": [
          "HR",
          "G1/S Checkpoint"
        ],
        "essential_pathways": [
          "PARP",
          "ATR/CHK1"
        ],
        "depmap_essentiality": {
          "BRCA1": 0.95,
          "TP53": 0.75
        },
        "clinical_evidence": {
          "olaparib_fda_approved": true,
          "response_rate": 0.7
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.66
      },
      "metrics": {
        "drug_match": true,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.66,
        "efficacy_score": 0.81,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.81,
            "confidence": 0.66,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.2,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.545,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.81,
            "confidence": 0.66,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.2,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.545,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.81,
            "confidence": 0.66,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.2,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.545,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.81,
            "confidence": 0.66,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.2,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.545,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.35,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.545,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.35,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.Q563* ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.545,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          }
        ],
        "run_signature": "aca20495-70af-44b1-9817-6f9946a269da",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "consider",
        "provenance": {
          "run_id": "aca20495-70af-44b1-9817-6f9946a269da",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 2
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.66,
            "tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.2
              }
            ],
            "S_contribution": 1.0,
            "P_contribution": 1.0,
            "E_contribution": 0.2,
            "pathway_disruption": {
              "ddr": 1.0,
              "tp53": 0.8
            }
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_006",
      "ground_truth": {
        "synthetic_lethality_detected": false,
        "known_sl_pairs": [],
        "effective_drugs": [],
        "broken_pathways": [],
        "essential_pathways": [],
        "depmap_essentiality": {
          "OR4F5": 0.1
        },
        "clinical_evidence": {
          "note": "Benign variant, no known SL"
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.258
      },
      "metrics": {
        "drug_match": false,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.258,
        "efficacy_score": 0.0,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.258,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.258,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.258,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.0,
            "confidence": 0.258,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.0,
            "confidence": 0.258,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.0,
            "confidence": 0.258,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "OR4F5 p.V123M ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          }
        ],
        "run_signature": "71ff8553-cf0c-434f-8bad-1564640f294e",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "insufficient",
        "provenance": {
          "run_id": "71ff8553-cf0c-434f-8bad-1564640f294e",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 1
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.258,
            "tier": "insufficient",
            "badges": [],
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "S_contribution": 0.05,
            "P_contribution": 0.0,
            "E_contribution": 0.0,
            "pathway_disruption": {}
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_007",
      "ground_truth": {
        "synthetic_lethality_detected": false,
        "known_sl_pairs": [],
        "effective_drugs": [],
        "broken_pathways": [],
        "essential_pathways": [],
        "depmap_essentiality": {
          "HLA-A": 0.15
        },
        "clinical_evidence": {
          "note": "Non-essential gene, no SL expected"
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.217
      },
      "metrics": {
        "drug_match": false,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.217,
        "efficacy_score": 0.0,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.217,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "HLA-A p.A74T ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.217,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "HLA-A p.A74T ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.217,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "HLA-A p.A74T ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.0,
            "confidence": 0.217,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "HLA-A p.A74T ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.0,
            "confidence": 0.217,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "HLA-A p.A74T ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.0,
            "confidence": 0.217,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "HLA-A p.A74T ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.471,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          }
        ],
        "run_signature": "3583e574-ee3b-4463-876b-528dcf69b7a2",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "insufficient",
        "provenance": {
          "run_id": "3583e574-ee3b-4463-876b-528dcf69b7a2",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 1
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.217,
            "tier": "insufficient",
            "badges": [],
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "S_contribution": 0.05,
            "P_contribution": 0.0,
            "E_contribution": 0.0,
            "pathway_disruption": {}
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_008",
      "ground_truth": {
        "synthetic_lethality_detected": false,
        "known_sl_pairs": [],
        "effective_drugs": [
          "Trametinib"
        ],
        "broken_pathways": [
          "MAPK"
        ],
        "essential_pathways": [],
        "depmap_essentiality": {
          "KRAS": 0.25
        },
        "clinical_evidence": {
          "note": "KRAS mutation, but no SL relationship"
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.57
      },
      "metrics": {
        "drug_match": false,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.57,
        "efficacy_score": 0.0,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.57,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "KRAS p.G12D ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.8,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.57,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "KRAS p.G12D ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.8,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.0,
            "confidence": 0.57,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "KRAS p.G12D ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.8,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.0,
            "confidence": 0.57,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "KRAS p.G12D ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.8,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.0,
            "confidence": 0.57,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "KRAS p.G12D ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.8,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.0,
            "confidence": 0.57,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "KRAS p.G12D ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.622,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.8,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          }
        ],
        "run_signature": "db26b5c0-30a3-49f3-a8fe-c3cd8534cef3",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "insufficient",
        "provenance": {
          "run_id": "db26b5c0-30a3-49f3-a8fe-c3cd8534cef3",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 1
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.57,
            "tier": "insufficient",
            "badges": [],
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0001,
                "percentile": 0.8
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.8,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "S_contribution": 0.8,
            "P_contribution": 0.0,
            "E_contribution": 0.0,
            "pathway_disruption": {
              "ras_mapk": 0.8
            }
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_009",
      "ground_truth": {
        "synthetic_lethality_detected": true,
        "known_sl_pairs": [
          "BRCA1+PARP"
        ],
        "effective_drugs": [
          "Olaparib",
          "Niraparib"
        ],
        "broken_pathways": [
          "HR"
        ],
        "essential_pathways": [
          "PARP"
        ],
        "depmap_essentiality": {
          "BRCA1": 0.9,
          "PIK3CA": 0.3
        },
        "clinical_evidence": {
          "olaparib_fda_approved": true,
          "note": "BRCA1 SL dominates, PIK3CA secondary"
        }
      },
      "prediction_summary": {
        "top_drug": "BRAF inhibitor",
        "confidence": 0.56
      },
      "metrics": {
        "drug_match": false,
        "top_drug": "BRAF inhibitor",
        "top_drug_moa": "MAPK blockade",
        "confidence": 0.56,
        "efficacy_score": 0.3,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 5
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "BRAF inhibitor",
            "moa": "MAPK blockade",
            "efficacy_score": 0.3,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.E23* breast_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.5,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "MEK inhibitor",
            "moa": "MAPK downstream blockade",
            "efficacy_score": 0.3,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.E23* breast_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.5,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "IMiD",
            "moa": "immunomodulatory",
            "efficacy_score": 0.3,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.E23* breast_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.5,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "Proteasome inhibitor",
            "moa": "proteostasis stress",
            "efficacy_score": 0.3,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.E23* breast_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.5,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "Anti-CD38",
            "moa": "antibody",
            "efficacy_score": 0.3,
            "confidence": 0.56,
            "evidence_tier": "consider",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "vus",
              "review_status": "criteria_provided",
              "prior": 0.0
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA1 p.E23* breast_cancer",
              "citations": [],
              "clinvar": {
                "classification": "vus",
                "review_status": "criteria_provided"
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.5,
              "essentiality": 0.9,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          }
        ],
        "run_signature": "b5d90bf0-d577-4321-944f-40c28001cbac",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "consider",
        "provenance": {
          "run_id": "b5d90bf0-d577-4321-944f-40c28001cbac",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 2
          },
          "confidence_breakdown": {
            "top_drug": "BRAF inhibitor",
            "confidence": 0.56,
            "tier": "consider",
            "badges": [],
            "rationale": [
              {
                "type": "sequence",
                "value": 1.0,
                "percentile": 1.0
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.0
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "S_contribution": 1.0,
            "P_contribution": 0.0,
            "E_contribution": 0.0,
            "pathway_disruption": {
              "ddr": 1.0,
              "pi3k": 0.05
            }
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    },
    {
      "case_id": "SL_010",
      "ground_truth": {
        "synthetic_lethality_detected": true,
        "known_sl_pairs": [
          "BRCA2+PARP",
          "TP53+ATR"
        ],
        "effective_drugs": [
          "Olaparib",
          "Ceralasertib"
        ],
        "broken_pathways": [
          "HR",
          "G1/S Checkpoint"
        ],
        "essential_pathways": [
          "PARP",
          "ATR/CHK1"
        ],
        "depmap_essentiality": {
          "BRCA2": 0.85,
          "TP53": 0.72
        },
        "clinical_evidence": {
          "olaparib_fda_approved": true,
          "note": "Germline BRCA2 + somatic TP53"
        }
      },
      "prediction_summary": {
        "top_drug": "olaparib",
        "confidence": 0.505
      },
      "metrics": {
        "drug_match": true,
        "top_drug": "olaparib",
        "top_drug_moa": "PARP inhibitor",
        "confidence": 0.505,
        "efficacy_score": 0.465,
        "evo2_used": true,
        "sequence_score": 0.55,
        "pathway_score": null,
        "num_drugs_returned": 6
      },
      "full_prediction": {
        "drugs": [
          {
            "name": "olaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.465,
            "confidence": 0.505,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.491,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "niraparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.465,
            "confidence": 0.505,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.491,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "rucaparib",
            "moa": "PARP inhibitor",
            "efficacy_score": 0.465,
            "confidence": 0.505,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.491,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "carboplatin",
            "moa": "platinum alkylating agent",
            "efficacy_score": 0.465,
            "confidence": 0.505,
            "evidence_tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.491,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": false
          },
          {
            "name": "bevacizumab",
            "moa": "anti-VEGF",
            "efficacy_score": 0.0,
            "confidence": 0.217,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.491,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          },
          {
            "name": "pembrolizumab",
            "moa": "anti-PD-1",
            "efficacy_score": 0.0,
            "confidence": 0.217,
            "evidence_tier": "insufficient",
            "badges": [],
            "evidence_strength": 0.0,
            "citations": [],
            "citations_count": 0,
            "clinvar": {
              "classification": "pathogenic",
              "review_status": null,
              "prior": 0.05
            },
            "evidence_manifest": {
              "pubmed_query": "BRCA2 p.N372H ovarian_cancer",
              "citations": [],
              "clinvar": {
                "classification": "pathogenic",
                "review_status": null
              }
            },
            "insights": {
              "functionality": 0.55,
              "chromatin": 0.491,
              "essentiality": 0.35,
              "regulatory": 0.1
            },
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 0.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "meets_evidence_gate": false,
            "insufficient_signal": true
          }
        ],
        "run_signature": "bafb6d7e-fe24-4d0b-8503-c33bbf0d034a",
        "scoring_strategy": {
          "approach": "evo2_adaptive",
          "source": "unknown",
          "models_tested": [
            "evo2_7b"
          ],
          "windows_tested": [
            {
              "flank": 4096,
              "exon_delta": 0.0
            },
            {
              "flank": 8192,
              "exon_delta": 0.0
            },
            {
              "flank": 16384,
              "exon_delta": 0.0
            }
          ],
          "ablation_mode": "SPE"
        },
        "evidence_tier": "consider",
        "provenance": {
          "run_id": "bafb6d7e-fe24-4d0b-8503-c33bbf0d034a",
          "profile": "baseline",
          "cache": "miss",
          "flags": {
            "fusion_active": false,
            "evo_use_delta_only": true,
            "evidence_enabled": true,
            "confidence_v2": false
          },
          "sequence_scoring": {
            "mode": "evo2_adaptive",
            "count": 2
          },
          "confidence_breakdown": {
            "top_drug": "olaparib",
            "confidence": 0.505,
            "tier": "consider",
            "badges": [
              "PathwayAligned"
            ],
            "rationale": [
              {
                "type": "sequence",
                "value": 0.0,
                "percentile": 0.05
              },
              {
                "type": "pathway",
                "percentile": 1.0,
                "breakdown": {
                  "ras_mapk": 0.0,
                  "tp53": 0.8
                }
              },
              {
                "type": "evidence",
                "strength": 0.0
              }
            ],
            "S_contribution": 0.05,
            "P_contribution": 1.0,
            "E_contribution": 0.0,
            "pathway_disruption": {
              "ddr": 0.05,
              "tp53": 0.8
            }
          },
          "lifts": {
            "ablation_mode": "SPE"
          }
        }
      }
    }
  ]
}